The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
ABUS · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
CYCN · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | ABUS | CYCN | CLIR | TFX |
|---|---|---|---|---|
| Moat Score (0–100) | 33 (highest) | 33 (highest) | 33 (highest) | 33 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 53 | 33 | 65 (highest) | 20 |
| Pricing power | — | — | 21 | 89 (highest) |
| Returns on capital | 0 | 0 | 0 | 9 (highest) |
| Balance-sheet safety | 55 (highest) | 55 (highest) | 55 (highest) | 0 |
| Capital discipline | 24 | 44 | 24 | 47 (highest) |
| Price vs. high estimate | No price data | No price data | No price data | 16% above high estimate |
| Market cap | $841M | $14M | $17.3M | $5.9B |
| Moat tier | No moat | No moat | No moat | No moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |